<i>In Vitro</i>
            Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014

Pfaller, Michael A.; Sader, Hélio S.; Rhomberg, Paul R.; Flamm, Robert K.

doi:10.1128/aac.02609-16

Cited by 75 publications

(86 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delafloxacin is a broad‐spectrum antibiotic with activity against gram‐positive aerobic bacteria, gram‐negative aerobic bacteria, gram‐positive and gram‐negative anaerobes, and Mycobacterium tuberculosis . The antibacterial activity of delafloxacin is enhanced in acidic conditions for gram‐positive and gram‐negative organisms …”

Section: Microbiologic Activitymentioning

confidence: 99%

“…Delafloxacin has been shown to be less active than ciprofloxacin and levofloxacin against Serratia sp. and Citrobacter sp . Delafloxacin activity against Acinetobacter sp.…”

Section: Microbiologic Activitymentioning

confidence: 99%

“…Delafloxacin has equally potent binding preference for DNA gyrase and topoisomerase IV. Due to its dual targets, delafloxacin has a very broad spectrum of activity including activity against gram‐negative, atypical, anaerobic, and gram‐positive bacteria, including MRSA . Having a broad spectrum of activity is one benefit of dual targets; however, an additional benefit is the reduced selection of resistant mutants .…”

mentioning

confidence: 99%

“…Due to its dual targets, delafloxacin has a very broad spectrum of activity including activity against gram‐negative, atypical, anaerobic, and gram‐positive bacteria, including MRSA . Having a broad spectrum of activity is one benefit of dual targets; however, an additional benefit is the reduced selection of resistant mutants . In addition, delafloxacin has been shown to be more potent in acidic environments due to the molecule having a weak acid property .…”

mentioning

confidence: 99%

“…4 Having a broad spectrum of activity is one benefit of dual targets; however, an additional benefit is the reduced selection of resistant mutants. 4 In addition, delafloxacin has been shown to be more potent in acidic environments due to the molecule having a weak acid property. 5,6 The availability of both parenteral and oral formulations for delafloxacin distinguishes it from many of the currently available agents for MRSA infections, which are only available for intravenous (IV) administration.…”

mentioning

confidence: 99%

See 4 more Smart Citations

What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone

et al. 2017

View full text Add to dashboard Cite

Delafloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults using dosage regimens of 300 mg intravenously every 12 hours, 450 mg orally every 12 hours, or switching from intravenous to oral regimens for a 5-to 14-day treatment duration. Dosage adjustments in patients with severe renal dysfunction (estimated glomerular filtration rate [eGFR] = 15-29 ml/min/1.73 m 2 ) are not required for oral doses but should be decreased to 200 mg intravenously every 12 hours in patients requiring parenteral therapy. Due to insufficient data, use of delafloxacin is not recommended for patients on hemodialysis or with endstage renal disease (eGFR < 15 ml/min/1.73 m 2 ). Delafloxacin works through inhibition of DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential enzymes for bacterial DNA transcription, replication, repair, and recombination and exhibits bactericidal activity against gram-positive and gram-negative organisms through a concentration-dependent matter. Delafloxacin has a very broad spectrum of activity against atypical, anaerobic, and resistant gram-negative and gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. During phase 3 trials, the most common side effects associated with delafloxacin were gastrointestinal (nausea, diarrhea). Unlike other fluoroquinolones, there does not seem to be a risk of QTc prolongation or phototoxicity with delafloxacin. The availability of both parenteral and oral formulations for delafloxacin distinguishes it from many of the currently available agents approved for ABSSSIs. Phase 3 studies for the treatment of respiratory infections are currently under way, and future results of these studies will further help delineate the role of delafloxacin. KEY WORDS delafloxacin, fluoroquinolone, methicillin-resistant Staphylococcus aureus, skin infection.

show abstract

Section: Microbiologic Activitymentioning

confidence: 99%

“…Delafloxacin has been shown to be less active than ciprofloxacin and levofloxacin against Serratia sp. and Citrobacter sp . Delafloxacin activity against Acinetobacter sp.…”

Section: Microbiologic Activitymentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone

et al. 2017

View full text Add to dashboard Cite

show abstract

Challenges in severe community-acquired pneumonia: a point-of-view review

et al. 2019

View full text Add to dashboard Cite

Purpose: Severe community-acquired pneumonia (SCAP) is still associated with substantial morbidity and mortality. In this point-of-view review paper, a group of experts discuss the main controversies in SCAP: the role of severity scores to guide patient settings of care and empiric antibiotic therapy; the emergence of pathogens outside the core microorganisms of CAP; viral SCAP; the best empirical treatment; septic shock as the most lethal complication; and the need for new antibiotics. Methods: For all topics, the authors describe current controversies and evidence and provide recommendations and suggestions for future research. Evidence was based on meta-analyses, most recent RCTs and recent interventional or observational studies. Recommendations were reached by consensus of all the authors. Results and conclusions: The IDSA/ATS criteria remain the most pragmatic tool to predict ICU admission. The authors recommend a combination of a beta-lactam/beta-lactamase inhibitor or a third G cephalosporin plus a macrolide in most SCAP patients, and to empirically cover PES (P. aeruginosa, extended spectrum beta-lactamase producing Enterobacteriaceae, methicillin-resistant S. aureus) pathogens when at least two specific risk factors are present. In patients with influenza CAP, the authors recommend the use of oseltamivir and avoidance of the use of steroids. Corticosteroids can be used in case of refractory shock and high systemic inflammatory response.

show abstract